The mononuclear phagocyte system and its cytokine inflammatory networks in schizophrenia and bipolar disorder

References

• Drexhage RC, Padmos RC, de Wit H et al. Patients with schizophrenia show raised serum levels of the pro-inflammatory chemokine CCL2: association with the metabolic syndrome in patients? Schizophr. Res.102(1–3), 352–355 (2008).
   PubMedGoogle Scholar
• Padmos RC, Hillegers MH, Knijff EM et al. A discriminating messenger RNA signature for bipolar disorder formed by an aberrant expression of inflammatory genes in monocytes. Arch. Gen. Psychiatry65(4), 395–407 (2008).
   PubMed Web of Science ®Google Scholar
• Potvin S, Stip E, Sepehry AA, Gendron A, Bah R, Kouassi E. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol. Psychiatry63(8), 801–808 (2008).
   PubMed Web of Science ®Google Scholar
• Garver DL, Tamas RL, Holcomb JA. Elevated interleukin-6 in the cerebrospinal fluid of a previously delineated schizophrenia subtype. Neuropsychopharmacology28(8), 1515–1520 (2003).
   PubMed Web of Science ®Google Scholar
• Schuld A, Hinze-Selch D, Pollmacher T. [Cytokine network in patients with schizophrenia and its significance for the pathophysiology of the illness]. Nervenarzt.75(3), 215–226 (2004).
   PubMed Web of Science ®Google Scholar
• Smith RS. A comprehensive macrophage-T-lymphocyte theory of schizophrenia. Med. Hypotheses39(3), 248–257 (1992).
   PubMed Web of Science ®Google Scholar
• Smith RS, Maes M. The macrophage-T-lymphocyte theory of schizophrenia: additional evidence. Med. Hypotheses45(2), 135–141 (1995).
   PubMed Web of Science ®Google Scholar
• Bessis A, Bechade C, Bernard D, Roumier A. Microglial control of neuronal death and synaptic properties. Glia55(3), 233–238 (2007).
   PubMed Web of Science ®Google Scholar
• Chesnokova V, Melmed S. Minireview: neuro–immuno–endocrine modulation of the hypothalamic–pituitary–adrenal (HPA) axis by gp130 signaling molecules. Endocrinology143(5), 1571–1574 (2002).
   PubMed Web of Science ®Google Scholar
• Lawson C, Wolf S. ICAM-1 signaling in endothelial cells. Pharmacol. Rep.61(1), 22–32 (2009).
   PubMed Web of Science ®Google Scholar
• Witkowska AM, Borawska MH. Soluble intercellular adhesion molecule-1 (sICAM-1): an overview. Eur. Cytokine Netw.15(2), 91–98 (2004).
   PubMed Web of Science ®Google Scholar
• Simeoni E, Hoffmann MM, Winkelmann BR et al. Association between the A-2518G polymorphism in the monocyte chemoattractant protein-1 gene and insulin resistance and Type 2 diabetes mellitus. Diabetologia47(9), 1574–1580 (2004).
   PubMed Web of Science ®Google Scholar
• Hoek A, Allaerts W, Leenen PJ, Schoemaker J, Drexhage HA. Dendritic cells and macrophages in the pituitary and the gonads. Evidence for their role in the fine regulation of the reproductive endocrine response. Eur. J. Endocrinol.136(1), 8–24 (1997).
   PubMedGoogle Scholar
• Simons PJ, Delemarre FG, Drexhage HA. A functional and phenotypic study on immune accessory cells isolated from the thyroids of Wistar and autoimmune-prone BB-DP rats. J. Autoimmun.15(4), 417–424 (2000).
   PubMedGoogle Scholar
• Simons PJ, Delemarre FG, Drexhage HA. Antigen-presenting dendritic cells as regulators of the growth of thyrocytes: a role of interleukin-1β and interleukin-6. Endocrinology139(7), 3148–3156 (1998).
   PubMedGoogle Scholar
• Geutskens SB, Otonkoski T, Pulkkinen MA, Drexhage HA, Leenen PJ. Macrophages in the murine pancreas and their involvement in fetal endocrine development in vitro. J. Leukoc. Biol.78(4), 845–852 (2005).
   PubMedGoogle Scholar
• Kim SU, de Vellis J. Microglia in health and disease. J. Neurosci. Res.81(3), 302–313 (2005).
   PubMed Web of Science ®Google Scholar
• Chamak B, Dobbertin A, Mallat M. Immunohistochemical detection of thrombospondin in microglia in the developing rat brain. Neuroscience69(1), 177–187 (1995).
   PubMedGoogle Scholar
• Christopherson KS, Ullian EM, Stokes CC et al. Thrombospondins are astrocyte-secreted proteins that promote CNS synaptogenesis. Cell120(3), 421–433 (2005).
   PubMed Web of Science ®Google Scholar
• Wakselman S, Bechade C, Roumier A, Bernard D, Triller A, Bessis A. Developmental neuronal death in hippocampus requires the microglial CD11b integrin and DAP12 immunoreceptor. J. Neurosci.28(32), 8138–8143 (2008).
   PubMedGoogle Scholar
• Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell133(5), 775–787 (2008).
   PubMed Web of Science ®Google Scholar
• Bruunsgaard H, Pedersen M, Pedersen BK. Aging and proinflammatory cytokines. Curr. Opin. Hematol.8(3), 131–136 (2001).
   PubMed Web of Science ®Google Scholar
• Schulz S, Schagdarsurengin U, Suss T, Muller-Werdan U, Werdan K, Glaser C. Relation between the tumor necrosis factor-α (TNF-α) gene and protein expression, and clinical, biochemical, and genetic markers: age, body mass index and uric acid are independent predictors for an elevated TNF-α plasma level in a complex risk model. Eur. Cytokine Netw.15(2), 105–111 (2004).
   PubMedGoogle Scholar
• Zandman-Goddard G, Peeva E, Shoenfeld Y. Gender and autoimmunity. Autoimmun. Rev.6(6), 366–372 (2007).
   PubMed Web of Science ®Google Scholar
• Herberth M, Krzyszton DN, Koethe D et al. Differential effects on T-cell function following exposure to serum from schizophrenia smokers. Mol. Psychiatry14(12), 1145 (2009).
   Google Scholar
• Tollerud DJ, Kurman CC, Nelson DL, Brown LM, Maloney EM, Blattner WA. Racial variation in serum-soluble interleukin-2 receptor levels: a population-based study of healthy smokers and nonsmokers. Clin. Immunol. Immunopathol.70(3), 274–279 (1994).
   PubMedGoogle Scholar
• Goral J, Karavitis J, Kovacs EJ. Exposure-dependent effects of ethanol on the innate immune system. Alcohol42(4), 237–247 (2008).
   PubMed Web of Science ®Google Scholar
• Newcomer JW. Medical risk in patients with bipolar disorder and schizophrenia. J. Clin. Psychiatry67(11), e16 (2006).
   PubMed Web of Science ®Google Scholar
• Thakore JH. Metabolic syndrome and schizophrenia. Br. J. Psychiatry186, 455–456 (2005).
   PubMed Web of Science ®Google Scholar
• Dahlman I, Kaaman M, Olsson T et al. A unique role of monocyte chemoattractant protein 1 among chemokines in adipose tissue of obese subjects. J. Clin. Endocrinol. Metab.90(10), 5834–5840 (2005).
   PubMed Web of Science ®Google Scholar
• Trayhurn P, Bing C, Wood IS. Adipose tissue and adipokines – energy regulation from the human perspective. J. Nutr.136(7 Suppl.), 1935S–1939S (2006).
   PubMed Web of Science ®Google Scholar
• Kamei N, Tobe K, Suzuki R et al. Overexpression of monocyte chemoattractant protein-1 in adipose tissues causes macrophage recruitment and insulin resistance. J. Biol. Chem.281(36), 26602–26614 (2006).
   PubMed Web of Science ®Google Scholar
• Cohen D, Dekker JJ, Peen J, Gispen-de Wied CC. Prevalence of diabetes mellitus in chronic schizophrenic inpatients in relation to long-term antipsychotic treatment. Eur. Neuropsychopharmacol.16(3), 187–194 (2006).
   PubMed Web of Science ®Google Scholar
• Bots ML, Baldassarre D, Simon A et al. Carotid intima-media thickness and coronary atherosclerosis: weak or strong relations? Eur. Heart J.28(4), 398–406 (2007).
   PubMed Web of Science ®Google Scholar
• Allison DB, Casey DE. Antipsychotic-induced weight gain: a review of the literature. J. Clin. Psychiatry62(Suppl. 7), 22–31 (2001).
   PubMed Web of Science ®Google Scholar
• Drzyzga L, Obuchowicz E, Marcinowska A, Herman ZS. Cytokines in schizophrenia and the effects of antipsychotic drugs. Brain Behav. Immun.20(6), 532–545 (2006).
   PubMed Web of Science ®Google Scholar
• Rybakowski JK. Antiviral and immunomodulatory effect of lithium. Pharmacopsychiatry33(5), 159–164 (2000).
   PubMed Web of Science ®Google Scholar
• Schwarz MJ, Riedel M, Ackenheil M, Muller N. Decreased levels of soluble intercellular adhesion molecule-1 (sICAM-1) in unmedicated and medicated schizophrenic patients. Biol. Psychiatry47(1), 29–33 (2000).
   PubMed Web of Science ®Google Scholar
• Kronig H, Riedel M, Schwarz MJ et al. ICAM G241A polymorphism and soluble ICAM-1 serum levels: evidence for an active immune process in schizophrenia. Neuroimmunomodulation12(1), 54–59 (2005).
   PubMedGoogle Scholar
• Teixeira AL, Reis HJ, Nicolato R et al. Increased serum levels of CCL11/eotaxin in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry (2007).
   Google Scholar
• Grundy SM, Brewer HB Jr, Cleeman JI et al. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation109(3), 433–438 (2004).
   PubMed Web of Science ®Google Scholar
• Theodoropoulou S, Spanakos G, Baxevanis CN et al. Cytokine serum levels, autologous mixed lymphocyte reaction and surface marker analysis in never medicated and chronically medicated schizophrenic patients. Schizophr. Res.47(1), 13–25 (2001).
   PubMed Web of Science ®Google Scholar
• Song XQ, Lv LX, Li WQ, Hao YH, Zhao JP. The interaction of nuclear factor-κ B and cytokines is associated with schizophrenia. Biol. Psychiatry65(6), 481–488 (2009).
   PubMed Web of Science ®Google Scholar
• Maes M, Bocchio Chiavetto L, Bignotti S et al. Effects of atypical antipsychotics on the inflammatory response system in schizophrenic patients resistant to treatment with typical neuroleptics. Eur. Neuropsychopharmacol.10(2), 119–124 (2000).
   PubMed Web of Science ®Google Scholar
• Naudin J, Capo C, Giusano B, Mege JL, Azorin JM. A differential role for interleukin-6 and tumor necrosis factor-α in schizophrenia? Schizophr. Res.26(2–3), 227–233 (1997).
   PubMed Web of Science ®Google Scholar
• Kim YK, Kim L, Lee MS. Relationships between interleukins, neurotransmitters and psychopathology in drug-free male schizophrenics. Schizophr. Res.44(3), 165–175 (2000).
   PubMed Web of Science ®Google Scholar
• Erbagci AB, Herken H, Koyluoglu O, Yilmaz N, Tarakcioglu M. Serum IL-1β, sIL-2R, IL-6, IL-8 and TNF-α in schizophrenic patients, relation with symptomatology and responsiveness to risperidone treatment. Mediators Inflamm.10(3), 109–115 (2001).
   PubMed Web of Science ®Google Scholar
• Ebrinc S, Top C, Oncul O, Basoglu C, Cavuslu S, Cetin M. Serum interleukin 1 a and interleukin 2 levels in patients with schizophrenia. J. Int. Med. Res.30(3), 314–317 (2002).
   PubMed Web of Science ®Google Scholar
• Haack M, Hinze-Selch D, Fenzel T et al. Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: effects of confounding factors and diagnosis. J. Psychiatr. Res.33(5), 407–418 (1999).
   PubMed Web of Science ®Google Scholar
• Ortiz-Dominguez A, Hernandez ME, Berlanga C et al. Immune variations in bipolar disorder: phasic differences. Bipolar Disord.9(6), 596–602 (2007).
   PubMed Web of Science ®Google Scholar
• Frommberger UH, Bauer J, Haselbauer P, Fraulin A, Riemann D, Berger M. Interleukin-6-(IL-6) plasma levels in depression and schizophrenia: comparison between the acute state and after remission. Eur. Arch. Psychiatry Clin. Neurosci.247(4), 228–233 (1997).
   PubMed Web of Science ®Google Scholar
• Lin A, Kenis G, Bignotti S et al. The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6. Schizophr. Res.32(1), 9–15 (1998).
   PubMed Web of Science ®Google Scholar
• Kaminska T, Wysocka A, Marmurowska-Michalowska H, Dubas-Slemp H, Kandefer-Szerszen M. Investigation of serum cytokine levels and cytokine production in whole blood cultures of paranoid schizophrenic patients. Arch. Immunol. Ther. Exp. (Warsz)49(6), 439–445 (2001).
   PubMed Web of Science ®Google Scholar
• Zhang XY, Zhou DF, Zhang PY, Wu GY, Cao LY, Shen YC. Elevated interleukin-2, interleukin-6 and interleukin-8 serum levels in neuroleptic-free schizophrenia: association with psychopathology. Schizophr. Res.57(2–3), 247–258 (2002).
   PubMed Web of Science ®Google Scholar
• Kim YK, Myint AM, Verkerk R, Scharpe S, Steinbusch H, Leonard B. Cytokine changes and tryptophan metabolites in medication-naive and medication-free schizophrenic patients. Neuropsychobiology59(2), 123–129 (2009).
   PubMed Web of Science ®Google Scholar
• Kudoh A, Takase H, Takahira Y, Katagai H, Takazawa T. Postoperative confusion in schizophrenic patients is affected by interleukin-6. J. Clin. Anesth.15(6), 455–462 (2003).
   PubMedGoogle Scholar
• Zhang XY, Zhou DF, Cao LY, Zhang PY, Wu GY, Shen YC. Changes in serum interleukin-2, -6, and -8 levels before and during treatment with risperidone and haloperidol: relationship to outcome in schizophrenia. J. Clin. Psychiatry65(7), 940–947 (2004).
   PubMed Web of Science ®Google Scholar
• Hori H, Yoshimura R, Yamada Y et al. Effects of olanzapine on plasma levels of catecholamine metabolites, cytokines, and brain-derived neurotrophic factor in schizophrenic patients. Int. Clin. Psychopharmacol.22(1), 21–27 (2007).
   PubMed Web of Science ®Google Scholar
• O’Brien SM, Scully P, Dinan TG. Increased tumor necrosis factor-α concentrations with interleukin-4 concentrations in exacerbations of schizophrenia. Psychiatry Res.160(3), 256–262 (2008).
   PubMed Web of Science ®Google Scholar
• Muller N, Empl M, Riedel M, Schwarz M, Ackenheil M. Neuroleptic treatment increases soluble IL-2 receptors and decreases soluble IL-6 receptors in schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci.247(6), 308–313 (1997).
   PubMed Web of Science ®Google Scholar
• Monteleone P, Fabrazzo M, Tortorella A, Maj M. Plasma levels of interleukin-6 and tumor necrosis factor α in chronic schizophrenia: effects of clozapine treatment. Psychiatry Res.71(1), 11–17 (1997).
   PubMed Web of Science ®Google Scholar
• Maes M, Meltzer HY, Bosmans E. Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine. Acta Psychiatr. Scand.89(5), 346–351 (1994).
   PubMed Web of Science ®Google Scholar
• Kauer-Sant’Anna M, Kapczinski F, Andreazza AC et al. Brain-derived neurotrophic factor and inflammatory markers in patients with early- vs. late-stage bipolar disorder. Int. J. Neuropsychopharmacol.12(4), 447–458 (2009).
   PubMed Web of Science ®Google Scholar
• Brietzke E, Stertz L, Fernandes B et al. Comparison of cytokine levels in depressed, manic and euthymic patients with bipolar disorder. J. Affect. Disord.116(3), 214–217 (2009).
   PubMed Web of Science ®Google Scholar
• O’Brien SM, Scully P, Scott LV, Dinan TG. Cytokine profiles in bipolar affective disorder: focus on acutely ill patients. J. Affect. Disord.90(2–3), 263–267 (2006).
   PubMed Web of Science ®Google Scholar
• Kudoh A, Sakai T, Ishihara H, Matsuki A. Plasma cytokine response to surgical stress in schizophrenic patients. Clin. Exp. Immunol.125(1), 89–93 (2001).
   PubMedGoogle Scholar
• Coelho FM, Reis HJ, Nicolato R et al. Increased serum levels of inflammatory markers in chronic institutionalized patients with schizophrenia. Neuroimmunomodulation15(2), 140–144 (2008).
   PubMed Web of Science ®Google Scholar
• Breunis MN, Kupka RW, Nolen WA et al. High numbers of circulating activated T cells and raised levels of serum IL-2 receptor in bipolar disorder. Biol. Psychiatry53(2), 157–165 (2003).
   PubMed Web of Science ®Google Scholar
• Kim YK, Myint AM, Lee BH et al. T-helper types 1, 2, and 3 cytokine interactions in symptomatic manic patients. Psychiatry Res.129(3), 267–272 (2004).
   PubMed Web of Science ®Google Scholar
• Kim YK, Myint AM, Lee BH et al. Th1, Th2 and Th3 cytokine alteration in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry28(7), 1129–1134 (2004).
   PubMed Web of Science ®Google Scholar
• Crespo-Facorro B, Carrasco-Marin E, Perez-Iglesias R et al. Interleukin-12 plasma levels in drug-naive patients with a first episode of psychosis: effects of antipsychotic drugs. Psychiatry Res.158(2), 206–216 (2008).
   PubMed Web of Science ®Google Scholar
• Kim YK, Suh IB, Kim H et al. The plasma levels of interleukin-12 in schizophrenia, major depression, and bipolar mania: effects of psychotropic drugs. Mol. Psychiatry7(10), 1107–1114 (2002).
   PubMed Web of Science ®Google Scholar
• Rothermundt M, Arolt V, Weitzsch C, Eckhoff D, Kirchner H. Immunological dysfunction in schizophrenia: a systematic approach. Neuropsychobiology37(4), 186–193 (1998).
   PubMedGoogle Scholar
• Zorrilla EP, Cannon TD, Gur RE, Kessler J. Leukocytes and organ-nonspecific autoantibodies in schizophrenics and their siblings: markers of vulnerability or disease? Biol. Psychiatry40(9), 825–833 (1996).
   PubMed Web of Science ®Google Scholar
• Falcone T, Fazio V, Marchi N, Franco K, Simon B, Janigro D. Do systemic inflammation and blood–brain barrier failure play a role in pediatric psychosis? Neurol. Psychiatry Brain Res.16(Suppl. 1), 19 (2009).
   Google Scholar
• Torres KC, Souza BR, Miranda DM et al. The leukocytes expressing DARPP-32 are reduced in patients with schizophrenia and bipolar disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry33(2), 214–219 (2009).
   PubMed Web of Science ®Google Scholar
• Nikkila HV, Muller K, Ahokas A, Miettinen K, Rimon R, Andersson LC. Accumulation of macrophages in the CSF of schizophrenic patients during acute psychotic episodes. Am. J. Psychiatry156(11), 1725–1729 (1999).
   PubMedGoogle Scholar
• Torres KC, Souza BR, Miranda DM et al. Expression of neuronal calcium sensor-1 (NCS-1) is decreased in leukocytes of schizophrenia and bipolar disorder patients. Prog. Neuropsychopharmacol. Biol. Psychiatry33(2), 229–234 (2009).
   PubMedGoogle Scholar
• Zhang XY, Zhou DF, Cao LY, Wu GY, Shen YC. Cortisol and cytokines in chronic and treatment-resistant patients with schizophrenia: association with psychopathology and response to antipsychotics. Neuropsychopharmacology30(8), 1532–1538 (2005).
   PubMedGoogle Scholar
• Maino K, Gruber R, Riedel M, Seitz N, Schwarz M, Muller N. T- and B-lymphocytes in patients with schizophrenia in acute psychotic episode and the course of the treatment. Psychiatry Res.152(2–3), 173–180 (2007).
   PubMed Web of Science ®Google Scholar
• Sperner-Unterweger B, Whitworth A, Kemmler G et al. T-cell subsets in schizophrenia: a comparison between drug-naive first episode patients and chronic schizophrenic patients. Schizophr. Res.38(1), 61–70 (1999).
   PubMedGoogle Scholar
• Cazzullo CL, Saresella M, Roda K et al. Increased levels of CD8+ and CD4+ 45RA+ lymphocytes in schizophrenic patients. Schizophr. Res.31(1), 49–55 (1998).
   PubMed Web of Science ®Google Scholar
• Henneberg A, Riedl B, Dumke HO, Kornhuber HH. T-lymphocyte subpopulations in schizophrenic patients. Eur. Arch. Psychiatry Neurol. Sci.239(5), 283–284 (1990).
   PubMedGoogle Scholar
• Kronfol Z, House JD. Immune function in mania. Biol. Psychiatry24(3), 341–343 (1988).
   PubMed Web of Science ®Google Scholar
• Craddock RM, Lockstone HE, Rider DA et al. Altered T-cell function in schizophrenia: a cellular model to investigate molecular disease mechanisms. PLoS ONE2(1), e692 (2007).
   PubMed Web of Science ®Google Scholar
• Zhang XY, Zhou DF, Qi LY et al. Superoxide dismutase and cytokines in chronic patients with schizophrenia: association with psychopathology and response to antipsychotics. Psychopharmacology (Berl.)204(1), 177–184 (2009).
   PubMed Web of Science ®Google Scholar
• Muller N, Schlesinger BC, Hadjamu M et al. Increased frequency of CD8 positive γ/δ T-lymphocytes (CD8+ γ/δ+) in unmedicated schizophrenic patients: relation to impairment of the blood-brain barrier and HLA-DPA*02011. Schizophr. Res.32(1), 69–71 (1998).
   PubMedGoogle Scholar
• Zorrilla EP, Luborsky L, McKay JR et al. The relationship of depression and stressors to immunological assays: a meta-analytic review. Brain Behav. Immun.15(3), 199–226 (2001).
   PubMed Web of Science ®Google Scholar
• Steiner J, Bielau H, Brisch R et al. Immunological aspects in the neurobiology of suicide: elevated microglial density in schizophrenia and depression is associated with suicide. J. Psychiatr. Res.42(2), 151–157 (2008).
   PubMed Web of Science ®Google Scholar
• Radewicz K, Garey LJ, Gentleman SM, Reynolds R. Increase in HLA-DR immunoreactive microglia in frontal and temporal cortex of chronic schizophrenics. J. Neuropathol. Exp. Neurol.59(2), 137–150 (2000).
   PubMedGoogle Scholar
• Wierzba-Bobrowicz T, Lewandowska E, Lechowicz W, Stepien T, Pasennik E. Quantitative analysis of activated microglia, ramified and damage of processes in the frontal and temporal lobes of chronic schizophrenics. Folia Neuropathol.43(2), 81–89 (2005).
   PubMed Web of Science ®Google Scholar
• Arnold SE, Trojanowski JQ, Gur RE, Blackwell P, Han LY, Choi C. Absence of neurodegeneration and neural injury in the cerebral cortex in a sample of elderly patients with schizophrenia. Arch. Gen. Psychiatry55(3), 225–232 (1998).
   PubMedGoogle Scholar
• Togo T, Akiyama H, Kondo H et al. Expression of CD40 in the brain of Alzheimer’s disease and other neurological diseases. Brain Res.885(1), 117–121 (2000).
   PubMedGoogle Scholar
• Falke E, Han LY, Arnold SE. Absence of neurodegeneration in the thalamus and caudate of elderly patients with schizophrenia. Psychiatry Res.93(2), 103–110 (2000).
   PubMedGoogle Scholar
• Thomas AJ, Davis S, Ferrier IN, Kalaria RN, O’Brien JT. Elevation of cell adhesion molecule immunoreactivity in the anterior cingulate cortex in bipolar disorder. Biol. Psychiatry55(6), 652–655 (2004).
   PubMed Web of Science ®Google Scholar
• Doorduin J, Klein HC, Dierckx RA, James M, Kassiou M, de Vries EF. [(11)C]-DPA-713 and [(18)F]-DPA-714 as new PET tracers for TSPO: a comparison with [(11)C]-(R)-PK11195 in a rat model of herpes encephalitis. Mol. Imaging Biol.11(6), 386–398 (2009).
   PubMedGoogle Scholar
• van Berckel BN, Bossong MG, Boellaard R et al. Microglia activation in recent-onset schizophrenia: a quantitative (R)-[11C]PK11195 positron emission tomography study. Biol. Psychiatry64(9), 820–822 (2008).
   PubMed Web of Science ®Google Scholar
• Hebenstreit GF, Fellerer K, Fichte K et al. Rolipram in major depressive disorder: results of a double-blind comparative study with imipramine. Pharmacopsychiatry22(4), 156–160 (1989).
   PubMed Web of Science ®Google Scholar
• Soczynska JK, Kennedy SH, Goldstein BI, Lachowski A, Woldeyohannes HO, McIntyre RS. The effect of tumor necrosis factor antagonists on mood and mental health-associated quality of life: novel hypothesis-driven treatments for bipolar depression? Neurotoxicology30(4), 497–521 (2009).
   PubMed Web of Science ®Google Scholar
• Jinno S, Fleischer F, Eckel S, Schmidt V, Kosaka T. Spatial arrangement of microglia in the mouse hippocampus: a stereological study in comparison with astrocytes. Glia55(13), 1334–1347 (2007).
   PubMedGoogle Scholar
• Sen J, Belli A. S100B in neuropathologic states: the CRP of the brain? J. Neurosci. Res.85(7), 1373–1380 (2007).
   PubMed Web of Science ®Google Scholar
• Hohoff C, Ponath G, Freitag CM et al. Risk variants in the S100B gene predict elevated S100B serum concentrations in healthy individuals. Am. J. Med. Genet. B Neuropsychiatr. Genet. (2009) (Epub ahead of print).
   Google Scholar
• Padmos RC, Van Baal GC, Vonk R et al. Genetic and environmental influences on pro-inflammatory monocytes in bipolar disorder: a twin study. Arch. Gen. Psychiatry66(9), 957-965 (2009).
   PubMed Web of Science ®Google Scholar
• Padmos RC, Schloot NC, Beyan H et al. Distinct monocyte gene-expression profiles in autoimmune diabetes. Diabetes57(10), 2768–2773 (2008).
   PubMedGoogle Scholar
• Malek TR. The main function of IL-2 is to promote the development of T regulatory cells. J. Leukoc. Biol.74(6), 961–965 (2003).
   PubMed Web of Science ®Google Scholar
• Ehrhardt RO, Ludviksson BR. When immunization leads to autoimmunity: chronic inflammation as a result of thymic and mucosal dysregulation in IL-2 knock-out mice. Int. Rev. Immunol.18(5–6), 591–612 (1999).
   PubMedGoogle Scholar
• Thompson C, Powrie F. Regulatory T cells. Curr. Opin. Pharmacol.4(4), 408–414 (2004).
   PubMedGoogle Scholar
• Akhondzadeh S, Tabatabaee M, Amini H et al. Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial. Schizophr. Res.90(1–3), 179–185 (2007).
   PubMed Web of Science ®Google Scholar
• Beshay E, Croze F, Prud’homme GJ. The phosphodiesterase inhibitors pentoxifylline and rolipram suppress macrophage activation and nitric oxide production in vitro and in vivo. Clin. Immunol.98(2), 272–279 (2001).
   PubMed Web of Science ®Google Scholar
• Heyes MP, Saito K, Crowley JS et al. Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease. Brain115(Pt 5), 1249–1273 (1992).
   PubMed Web of Science ®Google Scholar
• Mellor AL, Munn DH. Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation? Immunol. Today20(10), 469–473 (1999).
   PubMedGoogle Scholar
• Constant A, Castera L, Dantzer R et al. Mood alterations during interferon-a therapy in patients with chronic hepatitis C: evidence for an overlap between manic/hypomanic and depressive symptoms. J. Clin. Psychiatry66(8), 1050–1057 (2005).
   PubMed Web of Science ®Google Scholar
• Hauser P. Neuropsychiatric side effects of HCV therapy and their treatment: focus on IFN α-induced depression. Gastroenterol. Clin. North Am.33(1 Suppl.), S35–S50 (2004).
   Web of Science ®Google Scholar